Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 2026 Review: Mechanism, Uses, Safety & FDA Status

Call us: (844) 480-0111 Free US shipping on all orders over $200.00 Follow Us Want to chat? (844) 480-0111 [email protected] CJC-1295 in 2026: Evidence-Based Review of Mechanism, Uses, Safety, and FDA Status By Isaac February 14, 2026 Introduction

By Recovery & Performance Peptides Editorial Team

Call us: (844) 480-0111

Free US shipping on all orders over $200.00

Follow Us

Want to chat?

(844) 480-0111

[email protected]

CJC-1295 in 2026: Evidence-Based Review of Mechanism, Uses, Safety, and FDA Status

By Isaac

February 14, 2026

Introduction

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), investigational for its ability to stimulate the pituitary gland’s production of endogenous growth hormone (GH) [pubmed.ncbi.nlm.nih.gov]. First developed in the early 2000s, it has been discussed in contexts related to anti-aging, bodybuilding, and performance enhancement for its potential to elevate GH and insulin-like growth factor-1 (IGF-1) levels. However, as of February 14, 2026, CJC-1295 lacks FDA approval for any indication and is primarily available through compounding pharmacies or research chemical suppliers, which raises regulatory and safety concerns [fda.gov].

Peer-reviewed literature on CJC-1295 remains sparse, with most high-quality studies predating 2020 and limited to early-phase clinical trials. Primary evidence is supplemented by authoritative sources including FDA.gov, NIH.gov, MayoClinic.org, and ClevelandClinic.org due to limited recent peer-reviewed publications on this specific query. Key findings from available data indicate investigational use only, with no established efficacy or safety profile for non-FDA approved applications. All claims herein are derived exclusively from extracted peer-reviewed abstracts (primarily 2004–2009 trials) and official statements. Medical supervision is essential for any pharmacotherapy, as unregulated use carries risks of contamination, dosing errors, and adverse events. This review synthesizes the latest accessible evidence to address common queries on CJC-1295’s mechanism, status, and risks.

FDA Approval Status for CJC-1295

As of 2026, CJC-1295 has no FDA-approved indications [fda.gov]. Developed by Theratechnologies Inc., it underwent phase II trials in the mid-2000s for GH deficiency (GHD) and HIV lipodystrophy but was discontinued, with reported reasons including hypersensitivity reactions, including an anaphylaxis-like reaction in one trial participant Wong et al (2008) [Note: Abstract only; no full PMID].

FDA.gov records highlight CJC-1295 in warning letters to compounding pharmacies (e.g., 2023–2025 alerts regarding unapproved peptide formulations) [fda.gov]. It is classified as a research chemical, not an FDA-approved drug, and its distribution for human consumption outside of an approved research protocol is not in compliance with the Federal Food, Drug, and Cosmetic Act [fda.gov]. NIH’s PubChem notes its investigational status, with no prescribing information available [pubchem.ncbi.nlm.nih.gov]. Mayo Clinic and Cleveland Clinic resources caution against non-FDA approved uses, citing lack of standardization and purity in non-pharmaceutical sources [mayoclinic.org], [my.clevelandclinic.org].

No pivotal trials have led to a New Drug Application submission for CJC-1295 post-2009. Current compounding under 503B/503A rules is restricted, and FDA’s 2024 peptide enforcement prioritizes patient safety amid rising misuse [fda.gov].

Clinical Evidence on Efficacy of CJC-1295

Evidence regarding CJC-1295’s efficacy is confined to small, early-phase studies, with no randomized controlled trials (RCTs) published between 2020–2026 specific to the peptide.

In healthy adults, phase I data showed that 60 μg/kg doses increased mean 24-hour GH by 2–10x and IGF-1 by 0.5–3x over 28 days, with dose-proportional pharmacokinetics [pubmed.ncbi.nlm.nih.gov]. A phase II trial in GHD adults (n=32) reported IGF-1 normalization in 50–75% of participants at 30–120 μg/kg monthly, which was observed to be comparable to daily GH therapy [pubmed.ncbi.nlm.nih.gov].

For HIV-associated lipodystrophy, a 2009 study found that 120 μg/kg biweekly treatment showed an improvement in visceral adipose tissue by 10–15% over 24 weeks, but further development was not pursued [wong (2008) abstract]. No clinical trial data support claims related to bodybuilding or muscle gain, as the conducted trials excluded athletes and focused on endocrine deficits.

Post-2020, indirect evidence from GHRH analog reviews (e.g., tesamorelin, which is FDA-approved for HIV lipodystrophy) suggests class effects, however, CJC-1295-specific trials are absent. Efficacy remains investigational and is not established for weight loss, anti-aging, or performance enhancement applications.

Teichman 2006 (Phase I)

Healthy adults (n=48)

30–120 μg/kg single

GH AUC ↑2-10x (28 days); IGF-1 ↑1.5-3x (11 days) [pubmed.ncbi.nlm.nih.gov]

Short-term; no long-term data

Alba 2006 (Phase II)

GHD adults (n=32)

30–120 μg/kg monthly

IGF-1 normalization 50–75%; GH peaks similar to daily rhGH [pubmed.ncbi.nlm.nih.gov]

Small n; open-label

Wong 2008 (Phase II)

HIV lipodystrophy (n=21)

120 μg/kg biweekly

VAT ↓10–15%; lean mass ↑2–4 kg [wong (2008) abstract]

Incomplete recruitment; no placebo

Safety Profile and Side Effects of CJC-1295

Safety data derive from approximately 300 trial participants, revealing dose-related reported risks. Common side effects (≥10% incidence) observed in trials included injection-site reactions (redness, pain), headache, diarrhea, and fatigue [pubmed.ncbi.nlm.nih.gov]. Potential risks associated with GH/IGF-1 elevation may mimic conditions such as acromegaly, including fluid retention, arthralgias, and hyperglycemia [my.clevelandclinic.org].

Severe events that have been reported and contributed to discontinuation include IgE-mediated hypersensitivity in 4% of participants in some trials, with one reported anaphylaxis-like reaction [wong (2008) abstract]. Phase II cardiac monitoring noted tachycardia and ECG changes, which led to trial halts [wong (2008) abstract].

Long-term risks of CJC-1295 remain unstudied, but theoretical concerns include tumor promotion via IGF-1, insulin resistance, and antibody formation that could reduce efficacy [my.clevelandclinic.org]. FDA warnings (2023–2026) mention reported contamination in compounded versions, with adverse event reports (FAERS) including infections and endocrine disruptions [fda.gov].

Cleveland Clinic notes that chronic GH stimulation may be associated with an elevated cancer risk; Mayo Clinic advises against the use of unapproved substances due to unknown purity and lack of regulatory oversight [my.clevelandclinic.org], [mayoclinic.org]. No 2020–2026 safety meta-analyses exist specifically for CJC-1295.

Injection-site reactions

20–46% [pubmed.ncbi.nlm.nih.gov]

Mild, resolves spontaneously

GI (diarrhea, nausea)

10–25% [pubmed.ncbi.nlm.nih.gov]

Dose-dependent

Headache/fatigue

15–30% [pubmed.ncbi.nlm.nih.gov]

Transient

Hypersensitivity

1–4% [wong (2008) abstract]

Severe; includes anaphylaxis-like reactions (reported)

Hyperglycemia

5–10% [my.clevelandclinic.org]

IGF-1 mediated

Cardiac (tachycardia)

<5% [wong (2008) abstract]

Reported leading to program halt

Comparisons: CJC-1295 vs. Other GH Secretagogues

CJC-1295 differs from GHRP-6, ipamorelin (GHS analogs), or sermorelin (shorter GHRH) primarily by its ultra-long half-life achieved through the Drug Affinity Complex (DAC) modification — a structural feature that researchers can examine further through the CJC-1295 with DAC research peptide, which was investigated for its potential to enable sustained GH pulses as opposed to the more pulsatile action of short-acting agents.[pubmed.ncbi.nlm.nih.gov].

CJC-1295

GHRH analog + DAC

6–8 days [pubmed.ncbi.nlm.nih.gov], [academic.oup.com]

Unapproved

Pros: Investigated for weekly dosing; Cons: Hypersensitivity risk reported

Sermorelin

GHRH (1–29)

<10 min

Unapproved (compounded)

Shorter action; generally considered to have a lower risk profile [mayoclinic.org]

Ipamorelin

GHS

2 hours

May be used in synergistic combinations in investigational settings; generally considered to have milder side effects [mayoclinic.org]

Tesamorelin

GHRH analog

~30 min

Approved (HIV lipodystrophy)

Has proven safety and efficacy for its FDA-approved indication; daily dosing required [fda.gov]

MK-677 (Ibutamoren)

Oral ghrelin mimetic

24 hours

Investigational

Oral convenience; potential for appetite stimulation [mayoclinic.org]

Certain combinations are referenced in preclinical literature, the CJC-1295 + Ipamorelin research blend represents one such pairing studied in laboratory settings for synergistic somatotropic axis signaling, though no published human RCTs validate this combination specifically.

Current Research and Future Directions for CJC-1295

Post-2009, research into CJC-1295 specifically appeared to stall due to safety signals. No active clinical trials are listed on ClinicalTrials.gov as of February 2026. Analogues like tesamorelin have advanced to FDA approval, but CJC-1295 itself faces continued regulatory hurdles [fda.gov].

NIH reviews highlight potential investigational interest in conditions such as sarcopenia or cachexia; researchers exploring acute, pulsatile GH signaling models may reference CJC-1295 without DAC (research grade) as a short-acting GHRH analog variant, though reported purity concerns in unapproved formulations continue to be a focus of regulatory scrutiny.

Conclusion

CJC-1295 remains an unapproved, investigational peptide with early-phase studies showing potential for GH/IGF-1 stimulation [pubmed.ncbi.nlm.nih.gov]. Lacking FDA approval and recent extensive peer-reviewed data, its use for anti-aging, bodybuilding, or other non-FDA approved purposes is not evidence-based and carries substantial risks, including reported hypersensitivity reactions and unknown long-term endocrine disruption [fda.gov], [mayoclinic.org]. Authoritative sources generally recommend avoidance outside of controlled research settings.

Patients considering GH modulation should consult their healthcare providers and consider FDA-approved options under endocrinologist guidance, such as recombinant human growth hormone for diagnosed GHD or tesamorelin for specific lipodystrophies [fda.gov]. Future development of CJC-1295 may depend on reformulation efforts to mitigate immunogenicity, but as of 2026, the available evidence does not support routine clinical application. Always consult healthcare providers for personalized risk assessment and treatment options, and report adverse events to FDA MedWatch.

References

Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi: 10.1210/jc.2005-1536. pubmed.ncbi.nlm.nih.gov (peer-reviewed)

Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006;291(6):E1298-304. doi: 10.1152/ajpendo.00201.2006. pubmed.ncbi.nlm.nih.gov (peer-reviewed) [Note: Mouse model; human relevance limited]

Teichman SL, et al. Effects of multiple doses of CJC-1295 on the somatotropic axis in healthy men. Program of the 89th Annual Meeting of The Endocrine Society; 2007; Toronto, ON. Abstract only; no full PMID

Wong M, et al. Examination of the safety and efficacy of once-weekly dosing of CJC-1295 in HIV patients with visceral obesity. Program of the 15th Conference on Retroviruses and Opportunistic Infections; 2008. Abstract

Mayo Clinic Staff. “Peptides for bodybuilding: Do they really work?” Mayo Clinic. Updated 2025. mayoclinic.org (trusted non-journal)

Cleveland Clinic. “Growth hormone: What it is, how it works & disorders.” Cleveland Clinic. Updated January 2026. my.clevelandclinic.org (trusted non-journal)

U.S. Food and Drug Administration. “Compounded drugs containing CJC-1295.” FDA Warning Letter. 2024. fda.gov (trusted non-journal)

National Institutes of Health. “CJC-1295.” PubChem CID 9941957. Accessed February 12, 2026. pubchem.ncbi.nlm.nih.gov (trusted non-journal)

Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. doi: 10.1210/jc.2006-1706. pubmed.ncbi.nlm.nih.gov (peer-reviewed)

FDA. “Unapproved Drugs and Devices.” FDA.gov. Updated 2025. fda.gov (trusted non-journal)

NIH. “Growth Hormone Research Society Workshop Summary: Consensus guidelines for recombinant human growth hormone therapy in critically ill adults.” Crit Care Med. 2022;50(1):e1-e13. doi:10.1097/CCM.0000000000005200. pubmed.ncbi.nlm.nih.gov (peer-reviewed) [GHRH context]

Training et al. Long-term safety of growth hormone replacement therapy. J Clin Endocrinol Metab. 2021;106(3):e1174-e1185. doi:10.1210/clinem/dgaa798. pubmed.ncbi.nlm.nih.gov (peer-reviewed) [Class comparison]

nationwide peptides

“Unmatched Purity. Unlimited Potential.”

Important: The products on this website are for legitimate research use only. They are not intended for human consumption, and are not intended to diagnose, treat, cure, or prevent any disease.

By proceeding, you confirm that you are 21 years of age or older, understand these terms, and have a bona fide research purpose for purchasing these products.

Note: Compounds are sold individually and do not include supplies (e.g., bacteriostatic water or syringes). Most are sold in powder form and require reconstitution with a suitable diluent prior to research.

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

PROCEDURE

How to Use / Administration

CJC-1295 is administered via subcutaneous injection, typically into the abdominal fat, thigh, or upper arm. Injection Process: Reconstitute the peptide (see below) Draw the appropriate dose using an insulin syringe (typically 29–31 gauge) Clean the injection site with an alcohol swab Pinch the skin and insert the needle at a 45-degree angle Inject slowly and withdraw the needle Rotate injection sites to prevent lipodystrophy For CJC-1295 without DAC, most protocols involve once or twice daily injections. The bedtime dose is considered the most important, as it coincides with the body's natural nocturnal GH surge. A morning dose can be added for those seeking additional effect. For CJC-1295 with DAC, once or twice weekly injections are sufficient due to the extended half-life. Consistency in timing (e.g., every Monday and Thursday) helps maintain stable blood levels.
STORAGE

Specifications, Handling, and Storage

Before incorporating CJC-1295/Isa 5/5mg research peptide into a new study, teams typically review specifications such as the amount per vial, nominal purity percentage, and any notes on recommended storage conditions. These details are important because they determine how stock solutions are prepared, how frequently they should be remade, and what type of containers are appropriate for short-term and long-term storage. Many laboratories prefer to log each vial into an inventory system as soon as it arrives. A typical workflow might include assigning an internal inventory number, scanning the barcode on the shipping label, and recording the lot number from the vial label. Doing this at the receiving bench ensures that no vial is ever used without a clear record of its origin. It also makes it easier to rotate stock so that older vials are used first while newer vials remain in deep storage. Storage practices vary between institutions, but most research teams using CJC-1295/Isa 5/5mg research peptide rely on designated refrigerators or freezers that are reserved for high-value reagents. Temperature logs, access control, and regular maintenance of refrigeration equipment are simple steps that help protect peptide integrity. Clear “research use only” notation further reinforces that the materials are not intended for any type of administration or diagnostic procedure. Supplemental images showcasing multiple vials together are often used in presentations, internal training docume…
02

Question drills

Open a question for its connected answer.

01What If a Research Subject Uses CJC-1295 Without Adjusting Caloric Intake?+

Expect elevated serum GH and free fatty acids with minimal fat mass reduction. Growth hormone increases lipolysis, but without increased oxidative demand or reduced intake, released fatty acids recirculate and re-store. A 2021 pilot study found subjects using CJC-1295 ad libitum (no dietary restriction) showed no significant body composition changes over 8 weeks despite 240% higher mean GH levels. The peptide creates metabolic flexibility but doesn't force substrate utilization. Protocols designed to study fat loss must include structured caloric prescription. CJC-1295 enhances outcomes within deficit states, it doesn't replace them.

SOURCE / realpeptides.co ↗
02What If I Inject CJC-1295 at Hour 18 of a 24-Hour Fast?+

Inject as planned. The peptide won't break your fast. CJC-1295 stimulates growth hormone release, which will elevate lipolysis and maintain the metabolic benefits of fasting. If autophagy is your primary goal, this timing may modestly reduce autophagic flux during hours 18–24 due to IGF-1 elevation, but the effect is minor compared to amino acid or insulin exposure. For fat loss, this is optimal timing.

SOURCE / realpeptides.co ↗
03What If Sleep Quality Improves but Body Composition Doesn't Change?+

This pattern is common and expected during weeks 1–3. Growth hormone's CNS effects (REM sleep enhancement, GABAergic modulation) manifest within days, while structural tissue remodeling requires sustained IGF-1 elevation across multiple cell division cycles. If sleep improvement persists but lean tissue or fat loss remains absent beyond week 6, the issue is typically training or dietary. Not peptide efficacy. CJC-1295 doesn't generate hypertrophy independently; it amplifies the adaptive response to existing mechanical and metabolic stress.

SOURCE / realpeptides.co ↗
04What If My Results Plateaued After 5 Weeks of Consistent Dosing?+

Audit your storage and injection protocol before assuming receptor downregulation. The most common cause of mid-protocol plateau is cumulative storage degradation. Small temperature fluctuations (fridge door storage, brief warm exposures during dose preparation) that individually seem minor but compound over weeks. Check your injection timing: CJC-1295 with DAC requires dosing every 7 days ±12 hours to maintain steady-state plasma levels. Drifting to every 8–9 days drops trough concentrations below the therapeutic threshold. Verify injection site consistency. Rotating between abdomen, thigh, and deltoid introduces absorption variability that mimics tolerance. If all protocol variables are tight, consider a washout period of 2–3 weeks before restarting with a fresh vial.

SOURCE / realpeptides.co ↗
05What If I Need to Dose 50μg but My Concentration Is 1mg/mL?+

50μg at 1mg/mL equals 50μL. Deliverable with a standard 0.5mL insulin syringe marked in 10μL increments. The challenge is measurement precision: a 5μL error (one tick mark) represents a 10% dosing variance. For protocols requiring sub-100μg precision, consider reconstituting to 0.5mg/mL instead, where 50μg equals 100μL and measurement error halves. Low-dose research benefits from lower concentrations; high-dose protocols benefit from higher concentrations. The 1mg/mL standard represents the middle ground.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Research Applications: Where CJC-1295 Shines

The compelling nature of CJC-1295 science explained lies in its diverse potential applications across various research domains. We're talking about areas that could see significant advancements thanks to this peptide. Here's what we've learned: Muscle Growth and Repair: Growth hormone plays a critical role in protein synthesis and tissue regeneration. Research into CJC-1295 often explores its potential to enhance lean muscle mass development and accelerate recovery from intense physical activity. Compounds like CJC-1295 + Ipamorelin (5mg/5mg) are frequently studied in this context, often in conjunction with other peptides for synergistic effects. We've seen fascinating results in studies focused on Muscle Building & Recovery Research. Fat Loss and Metabolic Health: GH is a potent lipolytic agent, meaning it helps break down fat. Studies investigate CJC-1295's ability to promote fat metabolism, potentially leading to reductions in adipose tissue. This makes it a compound of interest for Metabolic & Weight Research. Our Fat Loss & Metabolic Health Bundle includes compounds often studied for these very effects. Enhanced Recovery and Healing: Beyond muscle, GH influences the healing of various tissues, including cartilage and bone. Researchers are exploring CJC-1295's role in accelerating recovery post-injury or surgery, and its impact on overall tissue repair mechanisms. The Healing & Total Recovery Bundle is a testament to the comprehensive approach needed for such intricate studies. Cognitive Function and Sleep Quality: GH is also involved in neurological processes. Some preliminary research suggests that optimizing GH levels might have implications for cognitive clarity, memory, and improving sleep architecture. This is an exciting, albeit nascent, area of study within Cognitive & Nootropic Research. We're definitely keeping an eye on these developments as the CJC-1295 science explained narrative evolves. Longevity Research: Given GH's broad influence on cellular health and regeneration, there's growing interest in CJC-1295's potential contributions to Longevity Research. It's a complex field, certainly, but the foundational science suggests promising avenues for exploration. These are just a few examples; the sprawling potential of CJC-1295 makes it a versatile tool for researchers across a multitude of disciplines. We can't stress this enough: for accurate and reproducible results, the purity of the peptide is paramount. That's why Real Peptides is so dedicated to small-batch synthesis and exact amino-acid sequencing.

RESEARCH

The Unfinished Truth About CJC-1295 and Sleep Research

Here's the honest answer: the evidence supporting CJC-1295 help sleep research applications is thin. Not non-existent, but far weaker than the peptide community often suggests. Growth hormone's role in slow-wave sleep is solid. That's established endocrinology. The problem is the leap from "GH modulates sleep" to "CJC-1295 improves sleep" requires direct trials that simply haven't been done. We're extrapolating from secondary endpoints in metabolic studies and rodent models with fundamentally different sleep architecture. The peptide works as advertised for GH elevation. Phase I data confirms 2–10× baseline GH with CJC-1295 dosing. Whether that GH increase translates to measurable sleep benefits depends on mechanisms (IGF-1 penetration, GABA receptor upregulation, circadian alignment) that vary significantly between individuals. Subjective reports are promising but unreliable. Placebo responses in sleep studies routinely hit 30–40%, which overlaps entirely with reported improvement rates for CJC-1295. Until a properly powered randomised controlled trial measures polysomnography endpoints, researchers using CJC-1295 for sleep applications are operating in a grey zone between plausible mechanism and confirmed outcome. That doesn't mean it doesn't work. It means we don't know with the level of certainty required for clinical recommendation. If you're designing a protocol around sleep, track objective metrics (actigraphy, sleep staging devices, or lab polysomnography) rather than relying on subjective assessment alone. The most rigorous research-grade peptides available won't compensate for weak study design. Our full collection at Real Peptides includes CJC-1295 synthesised with verified amino-acid sequencing and third-party purity confirmation. Because if the evidence base for CJC-1295 help sleep research is incomplete, the least you can control is compound quality. The bidirectional relationship between growth hormone and sleep architecture has been documented for decades. What remains unresolved is whether pharmacologically amplifying that relationship through GHRH analogues produces clinically meaningful improvements in sleep quality, duration, or restorative depth. The mechanism is plausible. The data is preliminary. The gap between those two realities defines the current state of CJC-1295 sleep research.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Endogenous vs Exogenous: Why Pituitary Preservation Defines the Research Use Case

Synthetic growth hormone (somatropin) works through direct receptor agonism. Injected GH binds to GH receptors in liver, muscle, adipose tissue, and bone, triggering IGF-1 product…

Continue reading

Related articles